2020
Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses
Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. The BMJ 2020, 368: l7078. PMID: 32024657, PMCID: PMC7190063, DOI: 10.1136/bmj.l7078.Peer-Reviewed Original ResearchConceptsIndividual patient-level dataCardiovascular related deathsCardiovascular riskMyocardial infarctionRelated deathsSummary-level dataHeart failureOdds ratioSystematic reviewIncreased cardiovascular riskMore myocardial infarctionsHeart failure eventsCochrane Central RegistryAcute myocardial infarctionMyocardial infarction eventsPatient-level dataRandom-effects modelWeb of ScienceAnalysis of trialsEligible trialsComposite outcomeAdverse eventsContinuity correctionControlled TrialsRosiglitazone treatment
2015
Weight Gain After Breast Cancer Diagnosis and All-Cause Mortality: Systematic Review and Meta-Analysis
Playdon MC, Bracken MB, Sanft TB, Ligibel JA, Harrigan M, Irwin ML. Weight Gain After Breast Cancer Diagnosis and All-Cause Mortality: Systematic Review and Meta-Analysis. Journal Of The National Cancer Institute 2015, 107: djv275. PMID: 26424778, PMCID: PMC4715249, DOI: 10.1093/jnci/djv275.Peer-Reviewed Original ResearchConceptsBody mass indexBreast cancer-specific mortalityCancer-specific mortalityCause mortalityWeight gainBreast cancer diagnosisBreast cancerStage I-IIIC breast cancerSystematic reviewPrediagnosis body mass indexWomen age 18 yearsPostdiagnosis weight gainCancer diagnosisCause mortality ratesBreast cancer mortalityAge 18 yearsWeb of ScienceCohort studyRecurrence outcomesMass indexCancer mortalityClinical trialsHigh riskMortality rateBody weight